Beta-thalassemia trait: an underrecognized risk for osteoporosis in postmenopausal women, warranting screening.

IF 0.7 Q4 ENDOCRINOLOGY & METABOLISM
Pooja Alipuria, Atush Alipuria
{"title":"Beta-thalassemia trait: an underrecognized risk for osteoporosis in postmenopausal women, warranting screening.","authors":"Pooja Alipuria, Atush Alipuria","doi":"10.1530/EDM-25-0073","DOIUrl":null,"url":null,"abstract":"<p><strong>Summary: </strong>This case series presents two postmenopausal women with beta-thalassemia trait who developed osteoporosis. Case 1 involves a woman in her 70s presenting with persistent lower back pain; imaging revealed a compression fracture at L2, and a DEXA scan confirmed osteoporosis with a forearm T-score of -3.8 and a femoral neck T-score of -2.5. Case 2 describes a woman in her late 50s with generalized bone pain and severe osteoporosis identified through DEXA scanning, with a lumbar spine T-score of -3.3. Both patients lacked classical secondary causes of bone loss, and laboratory evaluations were unremarkable. Family history was notable for osteoporosis in first-degree relatives, though the relatives' thalassemia status was unknown. Both patients declined injectable therapies and were managed with oral alendronate, calcium, and vitamin D supplementation. These cases highlight beta-thalassemia trait as a potential underrecognized risk factor for osteoporosis in postmenopausal women, suggesting the need for further research and consideration in clinical guidelines.</p><p><strong>Learning points: </strong>Beta-thalassemia trait may predispose to osteoporosis, even without iron overload or transfusion dependence. Postmenopausal women with beta-thalassemia trait should undergo early DEXA screening to prevent fractures. Patient preference impacts management: oral bisphosphonates are viable when injectables are refused. Guideline gaps: current osteoporosis protocols do not address beta-thalassemia trait as a risk factor.</p>","PeriodicalId":37467,"journal":{"name":"Endocrinology, Diabetes and Metabolism Case Reports","volume":"2025 3","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/EDM-25-0073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Summary: This case series presents two postmenopausal women with beta-thalassemia trait who developed osteoporosis. Case 1 involves a woman in her 70s presenting with persistent lower back pain; imaging revealed a compression fracture at L2, and a DEXA scan confirmed osteoporosis with a forearm T-score of -3.8 and a femoral neck T-score of -2.5. Case 2 describes a woman in her late 50s with generalized bone pain and severe osteoporosis identified through DEXA scanning, with a lumbar spine T-score of -3.3. Both patients lacked classical secondary causes of bone loss, and laboratory evaluations were unremarkable. Family history was notable for osteoporosis in first-degree relatives, though the relatives' thalassemia status was unknown. Both patients declined injectable therapies and were managed with oral alendronate, calcium, and vitamin D supplementation. These cases highlight beta-thalassemia trait as a potential underrecognized risk factor for osteoporosis in postmenopausal women, suggesting the need for further research and consideration in clinical guidelines.

Learning points: Beta-thalassemia trait may predispose to osteoporosis, even without iron overload or transfusion dependence. Postmenopausal women with beta-thalassemia trait should undergo early DEXA screening to prevent fractures. Patient preference impacts management: oral bisphosphonates are viable when injectables are refused. Guideline gaps: current osteoporosis protocols do not address beta-thalassemia trait as a risk factor.

Abstract Image

-地中海贫血特征:绝经后妇女骨质疏松症的未被充分认识的风险,值得筛查。
摘要:本病例系列介绍了两名绝经后患有-地中海贫血的妇女,她们发展为骨质疏松症。病例1涉及一名70多岁的妇女,表现为持续的腰痛;影像学显示L2处压缩性骨折,DEXA扫描证实骨质疏松,前臂t评分为-3.8,股骨颈t评分为-2.5。病例2描述了一名50多岁的女性,通过DEXA扫描发现全身骨痛和严重骨质疏松症,腰椎t评分为-3.3。两例患者均无典型继发性骨质流失,实验室评估无显著差异。一级亲属中有明显的骨质疏松家族史,但亲属的地中海贫血状况不详。两名患者均拒绝注射治疗,并接受口服阿仑膦酸钠、钙和维生素D补充治疗。这些病例强调了-地中海贫血特征是绝经后妇女骨质疏松症的潜在未被充分认识的危险因素,提示需要进一步研究和临床指南的考虑。学习要点:即使没有铁超载或输血依赖,地中海贫血特征也可能易患骨质疏松症。有-地中海贫血特征的绝经后妇女应进行早期DEXA筛查以预防骨折。患者偏好影响管理:当拒绝注射时,口服双膦酸盐是可行的。指南差距:目前的骨质疏松方案没有将-地中海贫血特征作为一个危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
142
审稿时长
9 weeks
期刊介绍: Endocrinology, Diabetes & Metabolism Case Reports publishes case reports on common and rare conditions in all areas of clinical endocrinology, diabetes and metabolism. Articles should include clear learning points which readers can use to inform medical education or clinical practice. The types of cases of interest to Endocrinology, Diabetes & Metabolism Case Reports include: -Insight into disease pathogenesis or mechanism of therapy - Novel diagnostic procedure - Novel treatment - Unique/unexpected symptoms or presentations of a disease - New disease or syndrome: presentations/diagnosis/management - Unusual effects of medical treatment - Error in diagnosis/pitfalls and caveats
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信